AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov) - P3 | N=423 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy of transarterial chemoembolization with and without apatinib in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis (ESMO Asia 2025) - "Compared with TACE alone, TACE combined with apatinib can significantly improve overall survival, objective response rate, and disease control rate in patients with intermediate- to advanced-stage HCC and should be recommended for suitable candidates with unresectable HCC. However, further well-designed RCTs are needed to confirm these findings and assess long-term safety and quality-of-life outcomes."

Retrospective data • Review • Hepatocellular Cancer • Oncology • Solid Tumor

Phase II study of adebrelimab combined with apatinib and nab-paclitaxel as second-line therapy in patients with advanced gastric cancer previously treated with immunotherapy (ESMO Asia 2025) - P2 | "The combination of Adebrelimab, Apatinib, and nab-Paclitaxel demonstrated modest efficacy and manageable safety as second-line treatment of advanced gastric cancer, representing a potential new option. Further randomized controlled trials are warranted to confirm the long-term efficacy and safety of this regimen."

Clinical • Metastases • P2 data • Gastric Cancer • Oncology • Solid Tumor

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting ➔ Completed

Trial completion • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Efficacy and safety comparison of small molecule anti-angiogenic drugs in the treatment of bone and soft tissue sarcomas : a network meta-analysis. (PubMed, BMC Cancer) - "Short-term efficacy of small-molecule anti-angiogenic TKIs varied across bone and soft tissue sarcomas, with trends favoring apatinib plus chemotherapy and anlotinib. However, substantial heterogeneity across studies, including sarcoma subtypes and prior therapies, limits definitive conclusions regarding comparative efficacy. A multidisciplinary team is needed to better manage the side effects."

Journal • Retrospective data • Review • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1α/CA9 signaling axis. (PubMed, Anticancer Drugs) - "This study elucidates a novel HDAC1/HIF1α/CA9 axis through which Apatinib induces ferroptosis. Targeting this pathway offers translational potential for overcoming Apatinib resistance in GC therapy."

Journal • Gastric Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • ACSL4 • CA9 • GPX4 • HDAC1 • HIF1A

Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes. (PubMed, J Gastrointest Cancer) - "Neoadjuvant immune checkpoint inhibition demonstrates high pathological and clinical response rates in dMMR/MSI-H colorectal cancer, with organ preservation achievable in selected rectal cancer patients. Neoadjuvant immunotherapy may become an alternative to surgery as the primary treatment for MSI-H/dMMR colorectal cancer if long-term quality of life is superior and toxicity and cost are competitive with standard surgical approaches. However, longer follow-up, predictive biomarkers, and randomized comparisons with upfront surgery are required before its routine clinical use."

Checkpoint inhibition • dMMR • IO biomarker • Journal • MSI-H • Review • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis (ASH 2024) - "TAs included BRAF inhibitor (vemurafenib [1]), MEK inhibitors (binimetinib [1], cobimetinib [2], trametinib [2]) and others (dasatinib [1], pazopanib [1], pexidartinib [1]), while ICIs were exclusively pembrolizumab (5)...TAs included BRAF inhibitor only (vemurafenib [3], dabrafenib [3]), MEK inhibitor only (trametinib [5]), BRAF + MEK inhibitors (2), and others (apatinib, anlotimib, bevacizumab, daratumumab, dasatinib, imatinib, pazopanib, sorafenib, or combinations [9]), while ICIs included pembrolizumab (4), nivolumab (4), tislelizumab (1), and sintilimab (1)...Conclusion TAs and ICIs can be considered in the management of MH. The responses to ICI therapy may be associated with the degree of PDL1 expression"

Checkpoint inhibition • Clinical • IO biomarker • Hematological Malignancies • Oncology • Sarcoma • Solid Tumor • DOCK8 • MAP2K1 • PD-L1 • PTPN11

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. (PubMed, Lancet Oncol) - P3 | "At final analysis, camrelizumab plus rivoceranib continued to show clinically meaningful survival improvement compared with sorafenib, with manageable safety. The extended follow-up further confirmed the benefit-to-risk profile of camrelizumab plus rivoceranib, supporting the combination as a new first-line treatment option for unresectable hepatocellular carcinoma."

Clinical • Journal • P3 data • Cardiovascular • Hepatocellular Cancer • Hypertension • Oncology • Respiratory Diseases • Solid Tumor

Comparative efficacy and safety of second-line therapies for patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Front Pharmacol) - "A thorough search was conducted up until 20 February 2025, across the PubMed, Medline, Embase, Cochrane Central, and Web of Science databases to find randomized controlled trials (RCTs) evaluating second-line monotherapies (such as Ramucirumab, Regorafenib, Pembrolizumab, Cabozantinib, and Apatinib) in adults with advanced HCC...Pembrolizumab and Ramucirumab had the most favorable balance of efficacy and tolerability among second-line treatments for advanced HCC and are indicated as optimal therapy alternatives to enhance clinical outcomes. https://www.crd.york.ac.uk/prospero/, identifier CRD420251010308."

Journal • Retrospective data • Review • Hepatocellular Cancer • Oncology • Solid Tumor

Comparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. (PubMed, Eur J Surg Oncol) - "The absence of direct head-to-head trials prompted the use of a network meta-analysis to compare the short-term efficacy of treatment regimens for gastric and gastroesophageal junction adenocarcinoma. Our findings suggest that immunotherapies or targeted therapies, when combined with chemotherapy, are likely to yield superior pathological responses compared to chemotherapy alone. However, these conclusions are based on intermediate endpoints and on limited study quality. Therefore, definitive ranking of these regimens requires validation through large, well-designed, direct randomized trials focused on long-term survival outcomes."

Clinical • Journal • Retrospective data • Review • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

HLB liver cancer combo beats Nexavar in phase 3 with nearly 2-year survival (Korea Biomedical Review) - "Landmark analyzes showed 77 percent of patients on the combo alive at 12 months versus 61 percent on sorafenib, 49 percent versus 33 percent at 24 months and 38 percent versus 25 percent at 36 months, despite more patients in the sorafenib arm receiving subsequent systemic therapy, including immunotherapy and targeted drugs. Median progression-free survival was 5.6 months with camrelizumab plus riboceranib and 3.7 months with sorafenib, with a hazard ratio of 0.54."

P3 data • Hepatocellular Cancer

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC (clinicaltrials.gov) - P3 | N=326 | Recruiting | Sponsor: Linhui Peng

New P3 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Innovative gene targeted treatments for osteosarcoma: a mini review of current clinical evidence and future prospects. (PubMed, Front Med (Lausanne)) - "Recent clinical studies have explored tyrosine kinase inhibitors (e.g., sorafenib, regorafenib), PI3K/Akt/mTOR inhibitors, angiogenesis modulators (e.g., apatinib), and immune checkpoint inhibitors. However, the rarity of osteosarcoma, trial design limitations, and treatment-related toxicities remain critical barriers. This review synthesizes current evidence and underscores the need for biomarker-driven, multimodal strategies to overcome resistance and improve long-term outcomes in osteosarcoma management."

IO biomarker • Journal • Review • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Hmgcs2 promotes malignant phenotype and apatinib resistance in her2-negative breast cancer via the rab23/β-catenin/tcf signaling axis (SABCS 2025) - "Mechanistic investigations revealed that RAB23-dependent β-catenin/TCF activation served as the primary driver of carcinogenesis.Conclusion Our study revealed a critical role of HMGCS2 in mediating Apatinib resistance in HER2-negative breast cancer. Mechanistically, HMGCS2 promoted malignant progression in HER2-negative breast cancer by activating the β-catenin/TCF transcriptional axis through RAB23-mediated signaling, highlighting HMGCS2 as a potential therapeutic target for precision oncology."

Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • HMGCS2

Precision neoadjuvant treatment with Artificial Intelligence assisted subtyping in HR+/HER2- breast cancer: a randomized, open-label, phase 2 trial FASCINATE-N (SABCS 2025) - P2 | "Precision treatments included six cycles of dalpicilib (CDK4/6 inhibitor) plus endocrine therapy every 4 weeks for endocrine-based group and six cycles of targeted therapy (SHR-1316 [PD-L1 inhibitor] for SNF2, fuzuloparib [PARP1 inhibitor] for SNF3 and apatinib [VEGFR inhibitor] for SNF4) plus nab-paclitaxel and carboplatin every 4 weeks for targeted-based group. NET plus CDK4/6 inhibitor was verified to replace chemotherapy with better tolerance in the endocrine-base group while precision therapy was proved promising clinical activity and manageable safety profile in the targeted-based group. (ClinicalTrials.gov: NCT05582499)."

Clinical • IO biomarker • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • SMARCA2

Exploratory phase II trial of camrelizumab (an anti-PD-1 antibody) combined with apatinib (a VEGFR-2 inhibitor) and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis (SABCS 2025) - P2 | "The treatment regimen consisted of camrelizumab (200 mg intravenously every 2 weeks, 12 cycles), apatinib (250 mg orally daily), and alternating chemotherapy [nab-paclitaxel (d1, 8, 15 every 4 weeks) for 4 cycles and epirubicin plus cyclophosphamide (every 2 weeks) for 4 cycles]. From June 2023 to April 2024, 35 patients were enrolled, of whom 1 patient withdrew due to adverse reaction intolerance. In conclusion, camrelizumab and apatinib combined with chemotherapy have good clinical efficacy and good safety as neoadjuvant treatments for stage II-III TNBC, warranting further investigation and potential clinical application. This innovative dual-score system stratifies pretreatment prognosis (PRPscore) and dynamically evaluates therapeutic efficacy (EAscore), enabling precision neoadjuvant optimization."

Biomarker • Clinical • IO biomarker • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD4 • CXCL1 • IL17A • IL18 • MMP7 • PD-L1 • TP53

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (clinicaltrials.gov) - P3 | N=262 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 ➔ 262 | Trial completion date: Jul 2027 ➔ Jul 2029 | Trial primary completion date: Jul 2026 ➔ Jul 2028

Enrollment change • Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Elevar plans resubmission of a New Drug Application to the U.S. Food and Drug Administration for the combination therapy of camrelizumab and rivoceranib in January 2026. (GlobeNewswire)

FDA filing • Hepatocellular Cancer

Optimizing Transarterial Chemoembolization in Hepatocellular Carcinoma: Current Strategies, Innovations, and Future Directions. (PubMed, Cureus) - "Emerging combination therapies, such as TACE with systemic agents like sorafenib, lenvatinib, and apatinib, or immunotherapies like atezolizumab-bevacizumab, show promise in improving progression-free and overall survival. Despite its established role, TACE is not without risks, including post-embolization syndrome and organ-specific ischemic complications. Continued research is essential to refine selection criteria, minimize adverse effects, and validate innovative approaches, ultimately improving outcomes for HCC patients across diverse clinical scenarios."

IO biomarker • Journal • Review • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • Transplantation

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Peking Union Medical College Hospital | N=100 ➔ 300

Checkpoint inhibition • Enrollment change • Hepatocellular Cancer • Oncology • Solid Tumor

New #ESMO25 podcast on HCC & PDAC! With @EileenMOReilly & @ArndtVogel we discuss: • IMbrave152: TIGIT in HCC • Periop camrelizumab+rivoceranib • TALENTOP: conversion after atezo-bev • KRAS G12D inhibitors in PDAC • CASSANDRA neoadjuvant chemo

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. (PubMed, CA Cancer J Clin) - "Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination-deficient patients. There was a PFS benefit trend among homologous recombination-proficient patients who received combination therapy compared with those who received monotherapy."

Clinical • Journal • P3 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HRD

Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: a prospective phase II clinical study (SNO 2025) - P2 | "Camrelizumab in combination with apatinib neoadjuvant therapy showed excellent efficacy in recurrent high-grade gliomas, and was significantly superior to PD1 inhibitor monotherapy neoadjuvant treatment in rGBM patients."

Clinical • Combination therapy • P2 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Gliosarcoma • High Grade Glioma • Oligodendroglioma • Sarcoma • Solid Tumor • KDR

Phase Ⅱ trial on apatinib treating for recurrent or progressive high-grade meningioma (SNO 2025) - "Our preliminary results showed treatment with apatinib achieved prolonged median PFS and OS in patients with recurrent or progressive high-grade meningioma, the related toxicities being manageable. Further investigation involving larger-size cohort is warranted to confirm the the efficacy of apatinib in this patient population."

Anorexia • Brain Cancer • Cardiovascular • Hypertension • Meningioma • Renal Disease • Solid Tumor